"CZ - \u010Cesk\u00E1 republika" . "Glycaemic control is important therapeutic target for Type 2 diabetic patients. These patients present with - insulin deficiency, - insulin resistance and - alpha cell dysfunction. To overcome failures of current therapy and to address the different underlying defects of pathology of Type 2 diabetes, a combined therapy of oral antidiabetic agents is used. The development of new agents that affect an insulin secretion, progression of beta cell failure and alpha cell dysfunction could be considered as an additional objective for the management of diabetes. The combination of such agents with other oral antidiabetic drugs could provide a long-term effect on good glycaemic control and reduce diabetic and cardiovascular complication in Type 2 diabetic patients."@en . . "0032-6739" . "Peror\u00E1ln\u00ED antidiabetika"@cs . "Oral antidiabetic drugs"@en . "Praktick\u00FD l\u00E9ka\u0159" . "2"^^ . . "Peror\u00E1ln\u00ED antidiabetika" . "1" . "2"^^ . . . "Kompenzace je d\u016Fle\u017Eit\u00FDm terapeutick\u00FDm c\u00EDlem pro pacienty s diabetes mellitus 2. typu. U t\u011Bchto pacient\u016F prokazujeme - poruchu inzulinov\u00E9 sekrece, - inzulinovou rezistenci, a - dysfunkci alfa bun\u011Bk pankreatu. Kombina\u010Dn\u00ED l\u00E9\u010Dba peror\u00E1ln\u00EDmi antidiabetiky je vedena snahou p\u0159ekonat nedostatky sou\u010Dasn\u00E9 terapie a zas\u00E1hnout v\u0161echny poruchy u diabetik\u016F 2. typu. Roz\u0161\u00ED\u0159en\u00ED l\u00E9\u010Debn\u00E9ho spektra o nov\u00E9 typy peror\u00E1ln\u00EDch antidiabetik ovliv\u0148uj\u00EDc\u00EDch sekreci inzulinu, ale i zpomalen\u00ED progrese selh\u00E1v\u00E1n\u00ED beta bun\u011Bk a dysfunkci alfa bun\u011Bk, se proto zd\u00E1 velmi pozitivn\u00EDm krokem pro terapii diabetu. Takov\u00E1 kombina\u010Dn\u00ED terapie by mohla zajistit dlouhodob\u011B dobrou kompenzaci a redukovat diabetick\u00E9 i kardiovaskul\u00E1rn\u00ED komplikace u diabetik\u016F 2. typu."@cs . . . . . . . "Peror\u00E1ln\u00ED antidiabetika"@cs . "diabetes mellitus Type 2; insulin sekretion; insulin resistance"@en . . "[EFAF1CA85A6F]" . . . "Vlas\u00E1kov\u00E1, Zuzana" . "Peror\u00E1ln\u00ED antidiabetika" . . "Oral antidiabetic drugs"@en . "219983" . "6"^^ . "RIV/00023001:_____/11:00002572!RIV12-MZ0-00023001" . "RIV/00023001:_____/11:00002572" . "Kompenzace je d\u016Fle\u017Eit\u00FDm terapeutick\u00FDm c\u00EDlem pro pacienty s diabetes mellitus 2. typu. U t\u011Bchto pacient\u016F prokazujeme - poruchu inzulinov\u00E9 sekrece, - inzulinovou rezistenci, a - dysfunkci alfa bun\u011Bk pankreatu. Kombina\u010Dn\u00ED l\u00E9\u010Dba peror\u00E1ln\u00EDmi antidiabetiky je vedena snahou p\u0159ekonat nedostatky sou\u010Dasn\u00E9 terapie a zas\u00E1hnout v\u0161echny poruchy u diabetik\u016F 2. typu. Roz\u0161\u00ED\u0159en\u00ED l\u00E9\u010Debn\u00E9ho spektra o nov\u00E9 typy peror\u00E1ln\u00EDch antidiabetik ovliv\u0148uj\u00EDc\u00EDch sekreci inzulinu, ale i zpomalen\u00ED progrese selh\u00E1v\u00E1n\u00ED beta bun\u011Bk a dysfunkci alfa bun\u011Bk, se proto zd\u00E1 velmi pozitivn\u00EDm krokem pro terapii diabetu. Takov\u00E1 kombina\u010Dn\u00ED terapie by mohla zajistit dlouhodob\u011B dobrou kompenzaci a redukovat diabetick\u00E9 i kardiovaskul\u00E1rn\u00ED komplikace u diabetik\u016F 2. typu." . . "Pelik\u00E1nov\u00E1, Terezie" . "91" . "N" . .